Kanzarkar Minakshi, Pathak Prem Prakash, Vaidya Mandar, Brumlik Charles, Choudhury Abhishek
Nanobiz LLC & Cocreate Consulting Pvt. Ltd.3322 US Hwy 22 West, Suite 421, Branchburg, NJ 08876, USA.
Pharm Pat Anal. 2015 Jan;4(1):29-36. doi: 10.4155/ppa.14.53.
Current insulin therapy for diabetes mellitus involves frequent dosing of subcutaneous injections, causing local discomfort, patient noncompliance, hypoglycemia and hyperinsulinemia, among others. While noninvasive therapy through oral delivery is greatly desired, there are challenges that include low bioavailability due to rapid enzymatic degradation in the stomach, inactivation and digestion by proteolytic enzymes in the intestinal lumen, poor permeability across the intestinal epithelium and poor stability. This article reviews patents that provide novel approaches for oral insulin delivery to the bloodstream through the GI tract.
目前用于治疗糖尿病的胰岛素疗法需要频繁进行皮下注射，会引起局部不适、患者依从性差、低血糖和高胰岛素血症等问题。虽然人们非常希望通过口服实现非侵入性治疗，但仍存在一些挑战，包括由于在胃中快速酶解导致生物利用度低、肠腔内蛋白水解酶使其失活和消化、跨肠上皮的通透性差以及稳定性差等。本文综述了通过胃肠道将口服胰岛素递送至血流的新方法的相关专利。
